Miami, FL – September 5, 2019 – TissueTechTM, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Sherry Saurini to the position of Vice President of Quality Assurance. In her new role, Ms. Saurini will have oversight for ensuring that the company is maintaining set requirements for the manufacture of birth tissue products for human use as the company moves closer to commercialization as a biologics provider.
Ms. Saurini is tasked with building and overseeing the company’s processes and procedures that systematically monitor different aspects of manufacturing operations. This includes conducting regular audits to detect and correct any problem or variance that fall outside established standards or requirements.
“Under Ms. Saurini’s leadership, TissueTech will continue to improve manufacturing processes, maximize efficiencies and maintain compliance with all regulatory guidelines,” said Frank Young, MD, PhD, Executive Vice President for Clinical, Regulatory Affairs and Quality. “She is a welcome addition to our Leadership Team. As Vice President of Quality Assurance, she will also lead the development, management and continual improvement of our organization-wide quality management system.”
Ms. Saurini brings more than 25 years of experience in quality assurance and regulatory affairs to TissueTech. Prior to joining TissueTech, she served as Vice President Quality for CryoLife, Inc, Vice President of Quality Assurance for Bard Medical, and Vice President of Quality Assurance and Regulatory Affairs for Plasma Surgical, Inc. She obtained her Bachelor of Arts Degree in Mathematics from Hanover College and her Master of Science in Mathematics with a concentration in Statistics from Georgia State University. Ms. Saurini is also an ASQ Certified Quality Engineer.
“Having solid quality processes in place are critical to the success of any manufacturing scale up,” said Saurini. “I am thrilled to be a part of this process. It is a wonderful opportunity for TissueTech, our physician customers and ultimately the patients who will benefit from new therapeutic options.”
About TissueTech, Inc.
TissueTech, Inc., and its wholly owned subsidiaries BioTissue, Inc. and Amniox Medical, Inc., are innovators and scientific leaders in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care and soft tissue products to support regenerative tissue healing using amniotic membrane and umbilical cord birth tissue donated from healthy, pre-screened mothers after elective cesarean section delivery of a live birth. The organization brings a skilled approach to innovation in evidence-based medicine with more than 20 years of clinical experience and more than 30 years of scientific research funded by the National Institutes of Health. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at www.tissuetech.com.